Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited? by unknown
Moodley and Goubran Thrombosis Journal  (2015) 13:33 
DOI 10.1186/s12959-015-0063-zREVIEW Open AccessShould lifelong anticoagulation for
unprovoked venous thromboembolism be revisited?
Otto Moodley and Hadi Goubran*Abstract
Venous thromboembolism [VTE] is a common medical condition that has significant morbidity and mortality. Although
stringent guidelines recommend lifelong anticoagulation for patients with unprovoked VTE, the optimal management
strategy for their long term treatment remains controversial.
Whereas in cancer-associated VTE and second unprovoked VTE lifelong anticoagulation is universally accepted, a
careful analysis of the benefit vs. risk of long-term anticoagulation following a first unprovoked VTE should be
considered as case fatality rates [CFR] from VTE appear more pronounced in the first few months. The CFR from
major bleeding remains constant throughout therapy. Therefore, the risk of bleeding may be underestimated
over longer treatment periods relative to the morbidity of recurrent VTE which appears to peak in the first year.
The current review highlights the balance between the recurrence risk and bleeding risks in the era of direct oral
anticoagulants.
Vitamin K antagonists have been the standard of care for over 50 years bearing significant bleeding risks. The
new oral anticoagulants [NOACs] have shown similar efficacy and perhaps a questionable improved safety profile
when compared to warfarin.
Aspirin has historically not been a useful agent in the management of VTE. However, two recent trials [WARFASA
and ASPIRE] showed a likely 20-30 % risk reduction when compared to placebo for recurrent VTE after initial
anticoagulation. The risk of major hemorrhage was low in both trials.
With the emergence of NOACs and the increased utility of aspirin, there are multiple therapeutic options for long
term management for VTE. Given comparable efficacy and improved safety of NOACs and aspirin, the risk benefit
of anticoagulation is improving.
A risk stratification model may help identifying patients at high risk for recurrence necessitating a lifelong
anticoagulation. This cohort should be separated from a low risk group that may benefit from clinical
observation, aspirin or NOACs.
Prospective clinical trials are needed to support these clinical observations.
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Venous thromboembolism (VTE) occurs for the first time
in ≈ 100 persons per 100,000 each year in the United
States, and rises exponentially from <5 cases per 100,000
persons at the age of 15 to ≈ 500 cases (0.5 %) per 100,000
persons at 80 years. Approximately one third of patients
with symptomatic VTE manifest pulmonary embolism
(PE), whereas two thirds manifest deep vein thrombosis
(DVT) alone [1].* Correspondence: Hadi.goubranmessiha@saskacancer.ca
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unless otherwise stated.VTE provoked by transient risk factors is associated
with a lower risk of recurrence necessitating 3–6
months of anticoagulation whereas unprovoked VTE
has a much higher recurrence risk and its treatment re-
mains challenging necessitating more prolonged secondary
prophylaxis [2].
Although, most guidelines advocate for long term antic-
oagulation for patients with unprovoked VTE [3, 4], advis-
ing patients and referring physicians about the optimal
duration of anticoagulation after acute unprovoked VTE
remains a very common PE/DVT consultation in the out-
patient setting. Because extending anticoagulation for ann Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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long-term reduction of recurrences following the discon-
tinuation of anticoagulation, indefinite treatment duration
should be reconsidered. However, case-fatality rate for
major bleeding in patients taking warfarin for more than
three months is higher than case-fatality rate of recurrent
VTE. Anticoagulant therapy is accordingly a double-edged
sword; evaluating patients is therefore complex as it re-
quires balancing the risks of recurrent VTE in the absence
of anticoagulation against the risks of bleeding complica-
tions with continued pharmacological therapy [5]. The dur-
ation of anticoagulation in this context is based on
discussion with our patients about their preferences and
the strength of the communicated message which is often
nuanced [6]. Physician knowledge, attitudes, and beliefs are
therefore partially responsible for the gap between actual
practice and international guidelines [7].
Worldwide, vitamin K antagonists [VKA] such as war-
farin remain the predominant anticoagulant prescribed for
VTE [8]. In 2010 alone, for example, more than 25 million
prescriptions were filled for warfarin in the USA [9]. Its
multiple interactions with food and other medications and
its narrow therapeutic range renders it a difficult agent to
utilize properly, being responsible for one-third of emer-
gency hospitalizations due to adverse drug events in pa-
tients 65 years of age or older [10]. Not surprisingly, in
view of its actual and perceived bleeding risks, warfarin
continues to be largely underused in clinical practice [11].
A recent study highlighted this underutilization; in a 1-year
adherence study conducted on 8040 VTE patients identi-
fied as being at high risk of recurrence (mean age 61 years,
59.4 % male), 76.9 % were not compliant with warfarin
therapy based on the proportion of days covered (more
than 80 % of days) and 51.5 % discontinued therapy [12].
With the advent of the new oral anticoagulants
[NOACs] characterized by their rapid onset of action, pre-
dictable pharmacokinetics and anticoagulant effect, spe-
cific coagulation enzyme target and their low potential for
drug or food interactions,[8] the risk benefit ratio may ap-
parently be more leaning towards benefit offering a poten-
tial for a safer long-term anticoagulation. NOACs are
more accepted by patients (especially the elderly) [13] as
they are prescribed in fixed doses and routine laboratory
coagulation monitoring is not required [14–17]. The drugs
that have completed phase 3 trials for VTE include: rivar-
oxaban and apixaban (competitive inhibitors of activated
factor X) and dabigatran, (direct inhibitor of thrombin).
To date, none of the drugs has a specific antidote [8]
potentially rendering their bleeding less amenable to
control.
Recurrence risk and fatality
The risk of recurrent thromboembolic disorders in the
10-year period following an episode of unprovoked VTEranges between 30 and 50 %. The rate is higher in pa-
tients with primary DVT than in those with primary
PE. The clinical presentation with a primary PE in-
creases by more than three times the risk of a new PE
episode over that with isolated DVT. Baseline parame-
ters that increase this risk are the proximal location of
DVT, obesity, male sex and old age, whereas the role of
thrombophilia is controversial [18].
Contemporary data from population studies on the inci-
dence and complications of VTE are limited. An observa-
tional cohort study was undertaken by Martinez et al.,
2014 [19], to estimate the incidence of first and recurrent
VTE. The cohort was identified from all patients in the
UK Clinical Practice Research Datalink (CPRD). Between
2001 and 2011, patients with first VTE were identified and
the subset without active cancer-related VTE observed for
up to 10 years for recurrence. 35,373 first VTE events
were reported with 16,708 (47.2 %) being unprovoked
among 26.9 million person-years of observation. The over-
all incidence rate (IR) of VTE was matching the previously
reported rates at 131.5 per 100,000 person-years and 107.0
(95 % CI, 105.8-108.2) after excluding cancer-associated
VTE. DVT was more common in the young whereas PE
was more common in the elderly. VTE recurrence oc-
curred in 3671 (Corrected IR 25.2 %). The IR for recur-
rence peaked in the first six months at around 11 per 100
person-years. It leveled out after three years and then
remained at around 2 per 100 person-years. The IRs for
recurrences was particularly high in young men [19].
Sex therefore seems to affect the risk of recurrence as
it was observed that men have about a 13 % higher risk
of recurrence than women [20]. The risk in women with
unprovoked first VTE was reported by other investiga-
tors to be around 3.2 % [21]. A slightly higher rate was
reported by a Japanese registry at 3.9 per 100 patient-
years also associated with a higher fatality rate [22].
A cochrane review looked at the recurrence rate in
eleven studies with a total of 3716 participants. A consist-
ent and strong reduction in the risk of recurrent venous
thromboembolic events was observed during prolonged
treatment with VKA (risk ratio (RR) 0.20, 95 % confidence
interval (CI) 0.11 to 0.38) independent of the period
elapsed since the thrombotic event. In addition, a substan-
tial increase in bleeding complications was observed for
patients receiving prolonged treatment during the entire
period after randomization (RR 2.60, 95 % CI 1.51 to 4.49)
while no reduction in mortality was noted during the en-
tire study period (RR 0.89, 95 % CI 0.66 to 1.21, P = 0.46).
It was therefore concluded that treatment with VKA
strongly reduces the risk of recurrent VTE for as long as
they are used. However, the absolute risk of recurrent
VTE declines over time while the risk for major bleeding
remains unchanged. Thus, the efficacy of VKA administra-
tion decreases over time since the index event [23].
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dates for prolonged anticoagulation was conducted and
concluded that patients with isolated distal DVT have a
significantly lower risk of overall VTE recurrence than did
patients with isolated proximal DVT but a similar risk of
serious recurrent VTE. Age > 50 years, unprovoked distal
DVT, and number of thrombosed veins (more than one)
influenced the risk of recurrence and may help to define
patients at significant risk of recurrence [24].
Although the incidence of VTE increases logarithmically
with age, patients > or = 65 years are less likely to have "un-
provoked" VTE than younger patients. Rates of recurrent
VTE do not differ significantly between patients 65 years
of age or older compared to younger patients [25].
No differences between NOACs and VKA were found
regarding recurrent VTE [26].
Recurrence is also often associated with a high fatality
rate in certain geographic areas. The case-fatality rate
(CFR) for recurrent VTE was reported to be 12.8 %
(95 % CI 7.99-19.1) in the Mediterranean region and
around 8.41 % (5.15-12.9) in other areas [27].
A relatively high rate and significant mortality associ-
ated with recurrence is therefore observed in a propor-
tion of the population that needs to be identified with
optimization of the duration of anticoagulation to cover
the maximal “at risk” period.
Bleeding risk
Observational studies have reported a wide range of
bleeding risks that differ 40-fold. This variation may be
caused by time trends, variation in bleeding definition
and study subject selection. The incidence of first-time
severe bleeding was reported to be 2.3 per 100 patient-
years (95 % confidence interval 1.4 to 3.1) in a Swedish
population. Male sex and use of drugs potentially inter-
acting with warfarin were the only independent risk fac-
tors of severe bleeding, with hazard ratios of 2.8 and 2.3,
respectively [28].
Most of the studies of risk of bleeding on VKAs are
derived from randomized controlled trials of highly se-
lected patients followed for less than 1 year. Khan and
Datta 2014 [29], reviewed patients in an anticoagulation
clinic who were treated for more than one year with a
VKA to prevent thrombosis recurrence. It was found
that many of these patients had serious comorbidities.
The latter is in contrast to many studies in which pa-
tients are highly selected. They found the overall rate
of bleeding was 10 episodes per 100 person-years.
Major bleeding episodes were 5.2 episodes per 100
person-years [29].
In a study conducted to report on bleeding with VKA
in a general practice context in the UK, the overall inci-
dence of first-time, idiopathic bleeding was 15.2 per 100
patient-years of current warfarin exposure: the incidenceof fatal/hospitalized and referred bleeding was 3.5 and
2.6 per 100 patient-years, respectively [30].
Drug-drug interaction is among the most important
determinants of bleeding in patients on warfarin. In a re-
cent study, 16.5 % of patients have developed bleeding
complications as a result of drug-drug interactions, cor-
relating with a marked prolongation of their INR [31].
The long experience with warfarin and its reversal in
the emergency rooms using oral and intravenous vitamin
K, FFP or prothrombin complex concentrate (PCC) in
the context of bleeding or urgent surgical interventions
underscore to a certain extent its bleeding risks.
The bleeding risk profile of the NOACs seemed initially
to be more favorable while maintaining a non-inferiority
efficacy versus warfarin. For the populations in the Mini-
Sentinel data assessment, the combined incidence rate
(Intracranial Hemorrhage [ICH] and Gastrointestinal
hemorrhage [GIH] events per 100,000 days at risk) was
1.8 to 2.6 times higher for new users of warfarin than for
new users of dabigatran. The incidence rate of GIH events
only per 100,000 days at risk was 1.6 to 2.2 times higher
for warfarin new users than for dabigatran new users, and
the incidence rate of ICH events only per 100,000 days at
risk was 2.1 to 3.0 times higher with warfarin than with
dabigatran. The results indicate that the observed bleeding
rates associated with new use of dabigatran do not appear
to be higher than the bleeding rates associated with new
use of warfarin [32].
As for the bleeding with rivaroxaban (HR, 0.55; 95 % CI,
0.35-0.89) and apixaban (HR, 0.31; 95 % CI, 0.15-0.62) the
anti-Xa inhibitors, a lower incidence of bleeding was
observed in comparison to that seen with the use of
LMWH-VKA combination followed by VKA. An even
lower proportion of patients experienced a major bleeding
event during 3 months of anticoagulation with rivaroxa-
ban, apixaban, and low molecular weight herparin-VKA
combination (0.49 %, 0.28 % and 0.89 % respectively;
95 % CI) [33].
In other studies comparing NOACs with warfarin
bleeding risks was significantly reduced by NOACs:
major bleeding by rivaroxaban (RR 0.55; 0.38 - 0.81) and
apixaban (RR 0.31; 0.17 - 0.55); major and clinically rele-
vant non-major bleeding by dabigatran (RR 0.63; 0.51 -
0.77), apixaban (RR 0.44; 0.36 - 0.55) and edoxaban (RR
0.81; 0.71 - 0.93). The absolute risk reduction for major
bleeding was 1 % for rivaroxaban and apixaban; and for
the composite bleeding endpoint 3.2 % for dabigatran,
5.4 % for apixaban, and 1.9 % for edoxaban [26].
Again, bleeding data for the NOACs are derived from
the carefully selected patients enrolled in clinical trials.
Dabigatran and to a lesser extent, rivaroxaban depend
largely on renal excretion for their elimination whereas
apixaban has a dual route of excretion. In elderly patients
maintained on prolonged NOACs therapy with declining
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the bleeding risk would increase logarithmically. Studies
specifically conducted on geriatric older, frail population
with multiple co-morbidities are therefore needed to
evaluate tolerance of NOACs in real life conditions.
In a study on real-life scenario for 1776 rivaroxaban-
treated patients, 762 patients (42.9 %) reported 1082
bleeding events during/within 3 days after last intake of
rivaroxaban (58.9 % minor, 35.0 % of non-major clinic-
ally relevant, and 6.1 % major bleeding according to
International Society on Thrombosis and Haemostasis
definition). In case of major bleeding, surgical or interven-
tional treatment was needed in 37.8 % and prothrombin
complex concentrate in 9.1 %. In the time-to-first-event
analysis, 100-patient-year rates of major bleeding was 4.1
(95 % confidence interval 2.5-6.4) for venous thrombo-
embolism patients. In the as-treated analysis, case fatality
rates of bleeding leading to hospitalizations were 5.1 %
and 6.3 % at days 30 and 90 after bleeding, respectively.
The data indicate therefore that, in real life, rates of
rivaroxaban-related major bleeding may be marginally
lower compared to the reported 5.2 % with VKA [29] and
that the outcome may be at least not worse than that of
major vitamin K antagonist bleeding [34]. Paradoxically, in
a meta-analysis by Holster et al. 2013 [35], looking at
gastrointestinal bleeding risks in patients with VTE or
acute coronary syndrome on NOACs, among the drugs
studied compared to VKA, the OR for apixaban was 1.23
(95 % CI, 0.56_2.73), the OR for dabigatran was 1.58 (95 %
CI, 1.29_1.93), the OR for edoxaban was 0.31 (95 % CI,
0.01_7.69), and the OR for rivaroxaban was 1.48 (95 % CI,
1.21_1.82). The overall OR for clinically relevant bleeding
in patients taking NOACs was 1.16 (95 % CI, 1.00_1.34)
and concluded that Studies on treatment of VTE or acute
coronary syndrome have shown that patients treated with
NOACs have an increased risk of GIB, compared with
those who receive standard care [35].
NOACs are therefore as efficient in the treatment of
VTE as VKA but might confer a potential for reduced risk
of bleeding complications. Indirect comparisons indicate
differences in the risk of clinically relevant bleeding events.
Important issues such as monitoring and reversal of
anticoagulation are still unresolved, but introduction of
NOACs increased the therapeutic spectrum and thereby
the potential for individualized therapy [26].
Benefit/risk ratio of prolonged anticoagulation
Despite the rigid guidelines, whether to continue oral
anticoagulant therapy indefinitely after completing 3 to
6 months of oral anticoagulant therapy for "unprovoked"
VTE is still an unanswered question in VTE manage-
ment in real life scenarios. This long-term decision
should be based on balancing the long-term mortality
risk from recurrent VTE, largely preventable with oralanticoagulant therapy, against the long-term mortality risk
of major bleeding, the major complication of oral anti-
coagulant therapy. There exist important knowledge gaps
in estimating the long-term mortality risk of recurrent
VTE in patients with unprovoked VTE who discontinue
therapy and the long-term mortality risk from major bleed-
ing in those who continue oral anticoagulant therapy.
These knowledge gaps are the source of uncertainty for pa-
tients and health care providers addressing this important
question [36]. These gaps are even wider as the recurrence
rates and bleeding risks with the NOACs are still scarce.
Lecumberri et al., 2013 [37], aimed to provide estimates
of the case-fatality rate (CFR) of recurrent VTE and major
bleeding during anticoagulation in a 'real life' population,
and to assess these outcomes according to the initial pres-
entation of VTE and its etiology. The study included
41,826 patients with confirmed VTE from the RIETE
registry who received different durations of anticoagula-
tion (mean 7.8 ± 0.6 months). During 27,110 patient-years,
the CFR was 12.1 % (95 % CI, 10.2-14.2) for recurrent
VTE, and 19.7 % (95 % CI, 17.4-22.1) for major bleeding.
During the first three months of anticoagulant therapy,
the CFR of recurrent VTE was 16.1 % (95 % CI, 13.6-
18.9), compared to 2.0 % (95 % CI, 0–4.2) beyond this
period. The CFR of bleeding was 20.2 % (95 % CI, 17.5-
23.1) during the first three months, compared to 18.2 %
(95 % CI, 14.0-23.2) beyond this period. The CFR of recur-
rent VTE was higher in patients initially presenting with
PE (18.5 %; 95 % CI, 15.3-22.1) than in those with DVT
(6.3 %; 95 % CI, 4.5-8.6), and in patients with provoked
VTE (16.3 %; 95 % CI, 13.6-19.4) than in those with un-
provoked VTE (5.5 %; 95 % CI, 3.5-8.0). In conclusion, the
CFR of recurrent VTE decreased over time during antic-
oagulation, while the CFR of major bleeding remained
stable reducing the benefit/risk ratio [37].
Another report pointed that VTE unrelated to a tran-
sient risk factor was associated with increased mortality
compared to mortality in patients with a transient risk
factor (hazard ratio (HR) 2.81; 95 % CI 1.40-5.62 [38].
Age is an important determining factor for de novo
“first unprovoked” VTE. Patients 65 years of age or older
have a much higher incidence of VTE compared to
younger subjects but are slightly less likely to have an
unprovoked event. Their rates of recurrence do not dif-
fer significantly when compared to younger patients
[25] but they tend to present with more PEs with a
higher case fatality [19]. The adjusted rates of major
bleeding increase by approximately two-fold, however
in older patients. Therefore, advancing age is not a pre-
dictor of recurrent VTE but is associated with more
PEs yet with a significant increase in major bleeding
episodes with VKA use [25].
Based on the reduced benefit/risk ratio noted with time,
and although guidelines suggest extended treatment for all
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high, De Jong et al., 2012 [38], emphasize that the
long-term risks of recurrent VTE off anticoagulation
are uncertain whereas the risk of bleeding associated
with anticoagulant therapy increases with age. In the
absence of evidence of reduced mortality or improved
quality of life with extended anticoagulant treatment,
they suggested a limited duration for most patients
after a first VTE. Extended treatment being considered
based mainly on patient preference [39].
Although the use of NOACs seems to tip the balance of
the benefit/risk ratio towards more benefit, one promising
solution to the current dilemma is risk stratification where
unprovoked VTE patients would be categorized as low or
high risk for recurrent VTE. Clinical decision making
would become less ambiguous and ultimately likely leading
to better outcomes [36]. Figure 1 illustrates the recurrence
rates of VTE compared to the risks of major bleeding.
Risk stratification model
VTE associated with active cancer, or a second unpro-
voked VTE, has a high risk of recurrence and should
be treated indefinitely. Furthermore, in cancer-associated
VTE recurrences a clinical risk assessment model (RAM)
has been presented. By combining 4 clinical patient char-
acteristics (sex, cancer type and stage, history of VTE), the
Ottawa score allows stratification of cancer patients ac-
cording to their VTE recurrence risk. The prediction tool
is successfully validated in more than 800 patients from 2
prospective VTE treatment studies [40].
The challenging question of optimal therapy for a first
isolated VTE can be addressed by considering the use of
risk assessment models [RAMs] or tools.
An increasing role is played by post-baseline parameters
such as the ultrasound assessment of residual vein throm-
bosis and the determination of D-dimer. New scenarios
are therefore, being offered through the identification ofFig. 1 Recurrence of DVT and PE over time after an unprovoked
episode compared to the risks of major bleeding with anticoagulation
using warfarin or rivaroxaban (modified from Martinez et al., 2014 [19])risk stratification models and by strategies that have the
potential to help identify patients in who anticoagulation
can be safely discontinued [18].
In an ideal world, genetic testing to determine suscepti-
bility for recurrence could also be used a good stratifica-
tion tool as multiple genetic SNP analysis is useful in the
prediction of recurrent thrombosis [41]. Such techniques
are not yet feasible in most centers.
In unprovoked VTE, however, residual vein thrombosis
was considered. Residual venous obstruction (RVO) was
assumed to improve the stratification of the risk of recur-
rence after unprovoked deep vein thrombosis (DVT), but
results from clinical studies and study-level meta-analyses
are conflicting [41].
An early study showed that RVO was associated with
a modestly increased risk of recurrent VTE in patients
with DVT (unprovoked and provoked). However, RVO
did not seem to be a predictor of recurrent VTE in pa-
tients with unprovoked DVT following anticoagulation
discontinuation [42].
A total of 2527 patients from 10 prospective studies
were included. RVO was found in 1380 patients
(55.1 %) after a median of six months from a first unpro-
voked DVT. Recurrent VTE occurred in 399 patients
(15.8 %) during a median follow-up of 23.3 months.
RVO was independently associated with recurrent VTE
(HR = 1.32, 95 % confidence interval [CI]: 1.06-1.65).
The association was stronger if RVO was detected
early, i.e. at three months after DVT (HR = 2.17; 95 %
CI: 1.11-4.25), but non-significant if detected later ren-
dering RVO a weak predictor of recurrence except
when performed at 3 months from the initiation of an-
ticoagulants [43]. This observation was also confirmed
by an earlier study reporting that RVO at the time of
VKA withdrawal was not associated with a statistically
significant higher risk of recurrence of VTE; pointing
that RVO assessment may not be useful to guide duration
of anticoagulation [44, 45]. In the subset of cancer pa-
tients, however, (usually not considered as unprovoked
VTE), the presence of RVO at attempted discontinu-
ation is associated with an increase in VTE recurrence
risk [44, 46, 47].
It was still unknown if residual perfusion defects (PD)
on lung scintigraphy are related to recurrent PE but a
recent study pointed that there is no significant associ-
ation found between PD >10 % and VTE recurrence ren-
dering this tool non-predictive of VTE recurrence [48].
The site of DVT was also explored in a complex predict-
ive model, the Vienna model, were proximal/PE were more
likely to recur than calf DVT [49] confirming previous re-
ports were also the number of thrombosed veins (more
than one) was a marker [24].
Over the past decades, there have been great advances
in the understanding of the pathogenesis of VTE through
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factors. However, it is well known that some subjects car-
rying several risk factors for VTE will never experience a
thrombotic episode while other individuals developed re-
current VTEs in their absence questioning the value of
thrombophilia screening [50]. It is now almost acceptable
that selective screening based on family history of throm-
bembolism is more cost-effective and clinically valuable
than universal screening [51].
As early as 2002, Palareti et al. [52], alluded to the
negative predictive value for VTE recurrence of the D-
Dimer test performed after 1 month of the discontinu-
ation of oral anticoagulation [52, 53].
The cumulative probability of recurrent VTE at 2 years
was 3.7 % (95 % CI, 0.9 %-6.5 %) among patients with
D-dimer levels of less than 250 ng/mL compared with
11.5 % (95 % CI, 8.0 %-15.0 %) among patients with
higher levels (P = .001) in larger studies [54].
The role of D-Dimer as a risk stratification tool seems
however, to be more defined. In a recent study on outpa-
tients with a first unprovoked VTE and after at least
3 months of anticoagulation, serial D-dimer measure-
ments were performed with predefined age/sex-specific
cutoffs and were followed for up to 2 years. Of 1010 pa-
tients, anticoagulation was stopped in 528 (52.3 %) with
persistently negative D-dimer who subsequently experi-
enced 25 recurrences (3.0 % patients-year; 95 % confi-
dence interval [CI], 2.0-4.4 %). It was therefore evident
that serial D-dimer measurement is suitable in clinical
practice for the identification of VTE patients in whom
anticoagulation can be safely discontinued [55]. In a more
recent study by Kearon et al. 2014 [55], the risk of recur-
rence in patients with a first unprovoked VTE who have a
negative D-dimer results is not low enough to justify stop-
ping anticoagulation in men but may be low enough to
justify the discontinuation in women [56].
Combining D-Dimer in a dyad model with RVO con-
solidated the value of D-Dimer done at one month [45]
and integrating the D-Dimer following the discontinu-
ation of anticoagulation in more complex predictive
models have also been attempted [24, 48].
Interestingly D-Dimer was also used as a biomarker dur-
ing warfarin therapy as high levels of D-Dimer predicted
major bleeding, cardiovascular events and all-cause
mortality [57].
More integrative predictive models for discontinuation
of anticoagulation have been advocated. The MEN-
HERDOO2 model is based on data prospectively derived
by Rodger et al., 2008 to identify patients with less than
a 3 % annual risk of recurrent VTE after their first event
of idiopathic proximal deep vein thrombosis or pulmon-
ary embolism. Risk factors for recurrent VTE were male
sex (the “men” of “Men and HERDOO2”), signs of post-
thrombotic syndrome, including Hyperpigmentation ofthe lower extremities, Edema or Redness of either leg, a
D-dimer level > 250 μg/L, Obesity (body mass index >
30 kg/m2, and Older age (>65 years). There was no com-
bination of clinical predictors that satisfied our criteria for
identifying a low-risk subgroup of men whereas women
with 0 or 1 risk factor may safely discontinue oral anti-
coagulant therapy after 6 months of therapy following a
first unprovoked venous thromboembolism [58].
The DASH score has also been advocated for, in this
scoring system, for each individual subject, the score is
calculated based on a sum of scores of four predictors:
age, sex, hormone use at the time of the VTE, and
D-dimer measured three weeks after stopping oral
anticoagulation. A score of +2 is assigned for abnormal
D-dimer, +1 for age 50 years old, +1 for male sex, and −2
for hormone use at onset of VTE (among women), gener-
ating a D2A1S1H−2 score. Therefore, for individuals with
an initial unprovoked VTE and a DASH score of 1, the an-
nual VTE recurrence risk is 3.1 percent which justifies
stopping anticoagulation after three to six months, assum-
ing (based on approximation of the annual bleeding inci-
dence) that a VTE recurrence rate of less than 5 percent is
an acceptable risk. In contrast, a DASH score of 2 is asso-
ciated with a VTE recurrence risk of 6.4 percent or higher,
a risk level sufficiently high to warrant prolonged anticoa-
gulation if the bleeding risk is acceptable [59].
The Vienna score is based, on the other hand on prese-
lected clinical and laboratory variables (age, sex, location
of VTE, body mass index, factor V Leiden, prothrombin
G20210A mutation, D-dimer, and in vitro thrombin
generation) and is difficult to apply in routine clinical
settings [60], the use of thrombophilia screen being
not universally acceptable as a screening tool for re-
current and even refuted as a stratification tool in an-
other Australian model [61].
Galanaud et al. 2014 [24] used simple predictive vari-
ables to conclude that after stopping anticoagulants, pa-
tients with isolated distal DVT have a significantly lower
risk of overall VTE recurrence than did patients with
isolated proximal DVT but a similar risk of serious re-
current VTE. Age > 50 years, unprovoked isolated distal
DVT, and number of thrombosed veins influenced the
risk of recurrence and may help to define patients at sig-
nificant risk of recurrence [24].
Although many RAMs have been advocated and seem
to help identify patients who would benefit from a more
prolonged anticoagulation, none has been widely vali-
dated and their use remains in the discretion domain of
the treating physicians.
Can aspirin tip the balance?
The first CRT to address the value of aspirin as an alterna-
tive to warfarin in unprovoked VTE following the comple-
tion of an initial warfarin therapy was the WARFASA trial
Moodley and Goubran Thrombosis Journal  (2015) 13:33 Page 7 of 9which was an investigator-initiated, double-blind study.
Patients with first-ever unprovoked venous thrombo-
embolism who had completed 6 to 18 months of oral anti-
coagulant treatment were randomly assigned to aspirin,
100 mg daily, or placebo for 2 years. The primary efficacy
outcome was recurrence of venous thromboembolism,
and major bleeding was the primary safety outcome.
Venous thromboembolism recurred in 28 of the 205
patients who received aspirin and in 43 of the 197 pa-
tients who received placebo (6.6 % vs. 11.2 % per year;
hazard ratio, 0.58; 95 % confidence interval [CI], 0.36
to 0.93). One patient in each treatment group had a
major bleeding episode. Adverse events were similar in
the two groups. It was concluded therefore, that aspirin
reduced the risk of recurrence when given to patients
with unprovoked venous thromboembolism who had
discontinued anticoagulant treatment, with no apparent
increase in the risk of major bleeding [62].
In the ASPIRE study published in the same year, as-
pirin, as compared with placebo, venous thromboembol-
ism recurred in 73 of 411 patients assigned to placebo
and in 57 of 411 assigned to aspirin (a rate of 6.5 % per
year vs. 4.8 % per year; hazard ratio with aspirin, 0.74;
95 % confidence interval [CI], 0.52 to 1.05; P = 0.09).
There was no significant between-group difference in
the rates of major or clinically relevant non-major bleed-
ing episodes (rate of 0.6 % per year with placebo vs.
1.1 % per year with aspirin, P = 0.22) or serious adverse
events. Aspirin therefore lead to a significant reduction
in the rate of major vascular events, with improved net
clinical benefit substantiating the earlier evidence of its
benefit when it is given to patients after initial anti-
coagulant therapy for a first episode of unprovoked ven-
ous thromboembolism [63].
These two trials, however, were not powered to detect
treatment effects for particular outcomes or subgroups.
The recently published INSPIRE collaboration used indi-
vidual patient data analysis of these trials to assess the
effect of aspirin versus placebo on recurrent VTE, major
vascular events and bleeding. Aspirin reduced recurrent
VTE (7.5 % year vs 5.1 % year) including DVT (HR 0.66)
and PE (HR 0.66) as well as, as expected, major vascular
events. After adjusting for adherence, reduction was
42 % and was more marked in men and older patients.
The overall risk of recurrence was reduced by more
than one third without any significant increase in the
risk of bleeding [64].
The recent data and data analysis of aspirin as alterna-
tive agent after the initial anticoagulation in patients
with unprovoked first isolated DVT are therefore very
encouraging especially if we apply the risk models were
male sex and old age are more prone to recurrence but
also prone to bleeding. Larger studies are needed to
confirm the efficacy and safety of this approach whichseems to tip the balance of the benefit/risk of long term
pharmacological therapy for these patients.
Conclusion
The optimal management strategy for long term treat-
ment of idiopathic VTE remains controversial. Cancer-
associated VTE and second objectively proven VTE
typically mandate a lifelong anticoagulation. It is clear
that there must be careful consideration of the benefits
of longterm thromboprophylaxis relative to the risk of
major hemorrhage for patients with first unprovoked
VTE.
CFR of VTE versus major hemorrhage is comparable
in the initial acute treatment phase. The CFR of recur-
rent VTE, however, decreases with time whereas the risk
of major hemorrhage remains consistently high for the
entire treatment time period.
Risk stratification models may help identifying patients
at higher risks of recurrence were anticoagulation seems
mandatory from low risk patients.
The historical standard of warfarin as the sole agent of
thromboprophylaxis may be undergoing a paradigm
shift. The emergence of the NOACs and reconsideration
of the benefit of aspirin give us additional clinical tools
to make a thoughtful, safe, and evidence based decisions
that will serve our patients most effectively.
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